Zoetis falls after cutting annual revenue forecast
04/11/2025 12:37
** Shares of animal healthcare co Zoetis ZTS.N fall 7.3% to $133 premarket ** ZTS forecasts 2025 revenue between $9.40 billion to $9.48 billion, down from its prior forecast of $9.45 billion to $9.60 billion ** Co reports Q3 adj.profit of $1.70/shr vs analysts' average estimate of $1.62/shr - LSEG data ** Co's quarterly revenue of $2.40 billion misses analysts' average expectation of $2.41 billion ** Up to last close, stock down ~11% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies